Abstract
Background: Given the rarity of esthesioneuroblastoma, it is difficult to validate a staging system. The purpose of this study was to investigate the utility of the Kadish staging system in esthesioneuroblastoma using the National Cancer Database (NCDB). Methods: One thousand one hundred sixty-seven patients with esthesioneuroblastoma were identified from the NCDB. Results: Five-year survival was 80.0% for Kadish A, 87.7% for Kadish B, 77.0% for Kadish C, and 49.5% for Kadish D. Kadish B had higher survival than Kadish A. More Kadish B patients received surgery with adjuvant therapy than Kadish A patients (41.6% vs 32.5%; P =.0038) and also had more positive margins (21.6% vs 11.3%; P =.03). There was no difference in age distribution, sex, race, or neck dissection status between the 2 groups. Conclusion: Kadish B had greater survival than Kadish A, but the treatment characteristics could not account for this difference. The utility of early-stage Kadish staging is uncertain and requires further study.
Original language | English |
---|---|
Pages (from-to) | 1962-1968 |
Number of pages | 7 |
Journal | Head and Neck |
Volume | 39 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- esthesioneuroblastoma
- head and neck cancer
- oncology
- outcomes
- statistics